Objective. The objective of this analysis was to describe patterns and determinants of cervical immunoglobulin A (IgA) and G (IgG) levels during the menstrual cycle.
Recent trials of prophylactic human papillomavirus (HPV) vaccines based on virus-like particles (VLPs) have shown high efficacy in preventing infections with the HPV types (i.e., HPV16 and HPV18, which cause ϳ70% of cervical cancers worldwide) in the vaccine formulation [1, 2] . The prophylactic protection conferred by these vaccines is likely mediated through HPVspecific neutralizing antibodies at the cervix [3] . Although vaccination induces high levels of circulating anti-HPV neutralizing antibodies systemically [3] , protection against HPV has to occur locally at the cervix. Systemic antibodies can transude into the cervix, with variable anti-HPV16 VLP antibody levels (ranging from 0.5% to 50% of the systemic levels) at the cervix following vaccination [4] .
It is not known whether and how local immunity at the cervix affects the long-term duration of HPV vaccine efficacy as antibody levels decrease. Given the potential impact of immunoglobulins on vaccine efficacy, it is important to investigate fluctuations in immunoglobulin levels as markers of cervical immunity during the menstrual cycle. An earlier study conducted in a group of women vaccinated with HPV16 VLP showed that IgA and IgG titers were highest during the follicular phase, decreasing around ovulation and increasing during the luteal phase [5] . We conducted this study to determine patterns in antibody levels among nonvaccinated women, to investigate fluctuations in total intrasubject and intersubject cervical levels of IgA and IgG dur-ing a single menstrual cycle, and to analyze the impact of demographic and behavioral factors on immunoglobulin patterns among women with a natural menstrual cycle (hereafter, "non-OC users") and women using an oral contraceptive (OC; hereafter, "OC users").
PARTICIPANTS, MATERIALS, AND METHODS
Study population. Data are from the National Cancer Institute-sponsored Proyecto Epidemiológico Guanacaste study [6, 7] . In brief, the primary aim of this population-based cohort study was to investigate the natural history of HPV infection and cervical intraepithelial neoplasia. Between 1993 and 1994, 10,049 women from Guanacaste province in Costa Rica were enrolled in the study. Participation among eligible women was Ͼ93%. At each visit, participants were interviewed to obtain information on demographic and behavioral characteristics and sexual practices. All women signed an informed consent at enrollment. The study was approved by the institutional review boards of the National Cancer Institute and Costa Rica.
A subset of women who were 25-35 years old, had an intact uterus, were not pregnant, and had no evidence of high-grade cervical lesions were contacted to participate in this study.
Initial contact. Women were visited at home, where we explained the purpose and procedures of this substudy. An appointment was made for clinic visits for women with regular menstrual cycles (cycle length, 25-35 days) who were willing to participate in the substudy.
Three clinic visits were scheduled to capture data at the follicular, periovulatory, and luteal phases of a single menstrual cycle. At the first clinic visit, further information regarding the study procedures was provided, and informed consent specific to this substudy was obtained. Non-OC users targeted their first (i.e., follicular phase) visit for days 5-8 after cycle onset, their second (i.e., periovulatory phase) visit for days 14 -16 after cycle onset, and their third (i.e., luteal phase) visit for days 19 -22 after cycle onset. Similar visits were scheduled for OC users, and, for consistency, we will refer to these visits as follicular, periovulatory, and luteral.
Data and specimen collection. At each visit, a questionnaire was administered to ascertain information on sexual behavior, reproductive history, current smoking status, douching history, recent illness, medication history, and vitamin use. Additional interview data collected as part of the main cohort study were also available. For non-OC users, ovulation was confirmed at the second clinic visit, using a urinary luteinizing hormone (LH) test kit (Ovuquick Conception Technologies).
At each visit, a pelvic examination was performed, during which cervical secretions were collected using cellulose-based Ultracell sponges (Medical Technologies). Sponges were gently placed in the cervical os for 30 s to passively absorb cervical secretions. Sponges were placed in cryovials, frozen immediately, and shipped to the United States in liquid nitrogen, where they were stored until extraction. Before extraction, the sponges were thawed on ice and weighed. The extraction process is described elsewhere [8] . In brief, 300 L of extraction buffer (PBS [Invitrogen]), 256 mmol/L of NaCl (Sigma-Aldrich), and 100 g/mL of Aprotinin (Sigma-Aldrich) were slowly added to the top of the sponge. Following incubation at 4°C for 30 min, sponges were centrifuged at 13,000 g for 15 min at 4°C. An additional 300 L of extraction buffer was added to the sponge, and it was immediately centrifuged again. Then, 5 L of extract was tested for blood contamination by use of Hemastix (Bayer) before the addition of 4 L of fetal calf serum. The extracts were aliquoted and frozen at Ϫ70°C until performance of an enzymelinked immunoassay (ELISA). At the final visit, cervical cells were also collected into PreservCyt solution (Cytyc) for liquid cytologic analysis and to determine the presence of infection with HPV, Chlamydia trachomatis, and Neisseria gonorrhea.
Determination of immunoglobulin levels. Cervical secretion extracts were diluted at 1:1000 and tested for total IgA and IgG levels, using an ELISA (Bethyl) performed in duplicate, in accordance with the manufacturer's instruction [9] .
Statistical analyses. IgA and IgG levels were standardized to account for differences in the volume of secretion collected. A total of 5-10 unused sponges randomly picked from each lot were weighed; the mean weight of these sponges was assumed to be the dry weight of all sponges from that lot. We standardized each IgA and IgG level by use of the following formula: [specimen weight Ϫ average dry sponge weight ϩ 0.6]/[specimen weight Ϫ average dry sponge weight], where 0.6 is defined as the weight of 600 L of extraction buffer. Standardized IgA and IgG levels were log-transformed to achieve a normal distribution. Geometric mean concentrations are presented.
One objective of this analysis was to investigate the determinants of IgA and IgG levels between women. We used linear regression models to obtain mean immunoglobulin levels among categories of a given covariate. Because there were 3 visits per woman and because values for each woman were autocorrelated, we used multivariate models for correlated data to determine factors independently associated with IgA and IgG levels. Generalized estimating equations models with an unstructured correlation structure were used to estimate SEs and coefficients adjusted for multiple observations for each woman [10] . Model coefficients were exponentiated and interpreted as the percentage change in immunoglobulin level for a given level of an exposure variable relative to the reference category. IgA and IgG findings were adjusted for sample weight when standardized. However, analyses suggested residual effects of weight on the immunoglobulin measurements; hence, we additionally adjusted for sample weight in our models.
A second objective of this analysis was to evaluate determinants of change in IgA and IgG levels between the follicular, periovulatory, and luteal visits within women. We assessed change in relation to immunoglobulin levels at the periovulatory visit, when levels were lowest for both non-OC users and OC users. Our rationale for choosing the lowest value as the reference was to facilitate the interpretation of the models. Thus, the outcome variable was constructed as the difference between logtransformed immunoglobulin levels at visits during the periovulatory and follicular phases, and similarly at periovulatory and luteal visits. We used linear regression to examine the effect of covariates on the magnitude of change in immunoglobulin levels between visits. Again, coefficients were exponentiated and can be interpreted as percentage changes.
All analyses were performed using Stata, version 9.2, and were stratified by OC use. Covariates that were statistically significant at P .10 in univariate models were entered into multivariate models. The final models were developed by including all covariates that were statistically significant in any of the multivariate models.
RESULTS

Population characteristics.
A total of 202 women were selected, of whom 199 women met the eligibility criteria, and 196 attended all 3 clinic visits. Of those who met the eligibility criteria, we excluded 17 who were breastfeeding at study entry and 28 whose menstrual cycle was either too short (Ͻ25 days; 9 women), too long (Ͼ36 days; 15 women), or unknown (4 women). Data for 154 women-69 OC users and 85 non-OC users-were included in the analysis ( figure 1 ). An additional 38 records were excluded because of low specimen weight, an indication that not enough secretion was collected. Women excluded were similar to those included in the analysis with respect to age, current smoking status, lifetime number of pregnancies, and HPV infection status (data not shown). For the 154 women included in the analysis, the median intervals from the end of the last menstrual period to the follicular, periovulatory, and luteal visits were 7 days (range, 5-8 days), 14 days (range, 13-17 days), and 19 days (range, 19 -22 days), respectively.
OC users were slightly younger than non-OC users (median age, 31 vs. 32 years; P ϭ .008). As expected, OC users differed from non-OC users with respect to the choice of birth control, with condom use, intrauterine device (IUD) use, and tubal ligation more common among non-OC users than OC users. No other differences were observed between OC users and non-OC users with respect to the other covariates evaluated (data not shown).
Patterns of IgA and IgG levels across the menstrual cycle. Figure 2 shows the log-transformed IgG and IgA measurements by the phase in cycle for 69 OC users and 85 non-OC users. Among non-OC users, IgA and IgG levels were higher during the follicular phase, with sharp decreases around ovulation, followed by increases during the luteal phase. OC users had stabler levels over time; however, a decrease in levels during the periovulatory period was still evident. Median titers were higher among OC users than non-OC users for IgA (0.38 vs. 0.23; P Ͻ .001) and IgG (1.03 vs. 0.44; P Ͻ .001). IgA and IgG levels were highly correlated (Spearman ϭ 0.76; P Ͻ .001) (figure 3). Although we targeted the second clinic visit to coincide with the expected time of ovulation, we were successful for only 13 of 85 women, based on testing for the surge in LH level. Ovulation typically occurs within 36 h after a surge in the LH level. The pattern observed for the women with an increased LH level was similar to that observed overall, although the magnitude of the decrease at midcycle was slightly more pronounced for those with a surge in LH level (figure 4). However, even among these women, there was wide variability, with some having higher levels at the start of the cycle and a more pronounced decrease around ovulation and others having a less pronounced change.
Intersubject factors associated with IgA and IgG levels. Univariate and multivariate effects of covariates on IgA and IgG during the menstrual cycle are presented in table 1. In the final multivariate model, increasing age, blood in the sample, and ectopy were associated with higher IgA and IgG levels, after adjustment for phase of the current menstrual cycle and specimen weight. Report of a recent illness was significantly associated with lower IgA and IgG levels. Higher immunoglobulin levels were associated with a greater lifetime number of pregnancies, although the association was significant only for IgA. IgG levels were significantly higher among women reporting current IUD use. Although we observed higher IgA and IgG levels among carcinogenic HPV-positive women in univariate models, the association was not significant in multivariate models. Higher IgA and IgG levels were not associated with current smoking, years since menarche, vaginal douching, vaginal discharge, talcum powder use, recent medication, C. trachomatis infection, N. gonorrhea infection, or vitamin use (data not shown). Similar patterns were observed when we examined patterns in IgA and IgG levels by covariates among all visits for the 13 non-OC users with a documented surge in the LH level (data not shown). Table 2 presents results of univariate and multivariate analyses of covariates of IgA and IgG levels among OC users. In the final multivariate model, blood in the sample and ectopy were associated with higher IgA and IgG levels, after adjustment for phase of the current cycle and specimen weight. Report of a recent illness was associated with lower IgA and IgG levels. A significant association was observed between lifetime number of pregnancies and IgG level. We did not observe an association with HPV detection or abnormal cytologic findings, current smoking, years since menarche, vaginal douching, vaginal discharge, talcum powder use, recent medication, C. trachomatis infection, N. gonorrhea infection, or vitamin use (data not shown).
Intrasubject factors associated with the magnitude of change in IgA and IgG levels. We observed average decreases of 78% in the IgA level and 83% in the IgG level between the follicular and periovulatory visits among non-OC users. For OC users, the decrease in levels between the follicular and periovulatory visits was 33% for IgA and 34% for IgG. Conversely, between the periovulatory and luteal visits, levels increased on average 58% for IgA and 62% for IgG among non-OC users, whereas among OC users, the respective increases between these visits were 2% for IgA and 15% for IgG (figure 2). Next, we evaluated factors associated with changes in IgA and IgG levels over the menstrual cycle. Although not statistically significant, among non-OC users (table 3), the percentage changes in the IgA and IgG levels between the follicular and periovulatory visits were greater for older women. Between the periovulatory and luteal visits, the opposite finding was seen (i.e., the percentage change for older women was less than that for younger women). The percentage change in IgA and IgG levels was lower among women who were sick during the cycle. Women with a greater increase in specimen weight between the follicular and periovulatory phases and between the periovulatory and luteal phases had smaller changes in IgA and IgG levels. Finally, higher immunoglobulin levels at visit 1 were associated with a smaller change between follicular and periovulatory visits but a higher change between periovulatory and luteal visits.
Similar patterns were observed among OC users (table 3) . Women with a greater increase in specimen weight between the follicular and periovulatory visits and between the periovulatory and luteal visits had a smaller change in IgA and IgG levels. Higher IgA and IgG levels at the follicular visit were associated with significantly lower changes between visits 1 and 2 but with greater changes between visits 2 and 3 (P ϭ not significant).
We did not observe any association with current smoking, years since menarche, vaginal douching, vaginal discharge, talcum powder use, recent medication or vitamin use, parity, years since first pregnancy, days since sexual activity, IUD use, blood in the sample, ectopy, and HPV detection or cytology status in either group (data not shown).
DISCUSSION
We were interested in understanding patterns and determinants of fluctuations in immunoglobulin levels at the cervix during the menstrual cycle because of the potential impact of fluctuations in virus-specific neutralizing antibody levels on the long-term efficacy of the newly licensed HPV vaccines. After vaccination, levels of anti-HPV antibodies in the genital tract are typically 10-fold lower than systemic levels, and blood titers have been shown to decrease with time since vaccination [5, 11, 12] . Although vaccine efficacy has, to date, been shown to remain high for up to 5 years after vaccination [3, 13] , the potential impact of these decreasing antibody levels on longer-term vaccine efficacy deserves further attention.
In our study, we demonstrated a sharp decrease in total IgA and IgG levels around ovulation among non-OC users, consistent with findings from a previous smaller study [14] . In addition, we observed that OC users typically had higher cervical immunoglobulin levels than non-OC users. However, even among OC users, a pattern of decreasing immunoglobulin levels at ovulation was observed, although it was less pronounced than that among non-OC users. Because systemic antibody levels decrease in the years after vaccination, that local levels are considerably less than systemic levels and that these levels decrease further at certain times during the menstrual cycle [5] underscore that surveillance of HPV-vaccinated women after vaccination should be continued.
The patterns in immunoglobulin levels during the menstrual cycle suggest an important role for sex hormones in the regulation of mucosal immunity. Early in the follicular phase, estradiol levels are low; later in this phase, levels increase exponentially and peak just before the surge in the LH level. At that time, estradiol levels plummet, but they increase again following ovulation and plateau during the midluteal phase of the menstrual cycle. Previous studies involving animals and humans demonstrated a role of sex hormones, particularly estradiol, in the regulation of cervical immunity [14, 15] . In one study [14] , immunoglobulin levels increased with increasing levels of estradiol. Because the surge in the level of LH signals a steep decrease in the estradiol level pursuant to ovulation, the lower immunoglobulin response we observed may be associated with lower estradiol levels. The higher immunoglobulin levels observed during the Figure 4 . Patterns of log-transformed IgA levels (A) and IgG levels (B) among 13 women with a natural menstrual cycle in whom a surge in the luteinizing hormone level occurred on the day of the periovulatory visit. Median IgA levels were 0.39, 0.04, and 0.36 mg/mL during the follicular, periovulatory, and luteal visits, and median IgG levels were 1.14, 0.09, and 0.62 mg/mL, respectively. luteal phase are consistent with a hormonal mechanism, as estradiol levels increase again during this phase of the cycle. In OC users, the highest cervical immunoglobulin levels occurred during the early phase of the cycle, corresponding to increasing levels of norethindrone, a synthetic form of estradiol, but decreased significantly during the final week, when the synthetic estrogen is no longer orally ingested. Finally, our finding of a sharp decrease in IgA and IgG levels at midcycle was particularly evident among the group of non-OC users with a confirmed surge in the LH level.
A unique feature of the present study was the large number of women evaluated. This allowed us to examine not only the overall immunoglobulin levels and patterns in cervical secretions over the menstrual cycle among non-OC users and OC users, but to explore demographic characteristics and lifestyle factors that might modulate these levels. In doing so, several correlates of immunoglobulin levels were observed.
Our finding that older age was associated with higher immunoglobulin levels, especially IgA levels among OC users, is consistent with previous reports [16] . Although all women in the study population were premenopausal, the age association is physiologically plausible because older women have lower volumes of cervical secretions and, thus, less diluted and more-concentrated immunoglobulin levels. Higher lifetime number of pregnancies was associated with higher immunoglobulin levels among OC users and non-OC users. The strongest effect was for IgA among non-OC users, consistent with a previous report in which local IgA and IgG levels in pregnant women were higher than those in nonpregnant women [17] . This association with lifetime number of pregnancies suggests that the effect of pregnancy-related hormonal changes may be retained after pregnancy has ended. To examine this further, we restricted our final tables to women whose most recent pregnancy was Ͼ2 years before our study and observed the same trends found in the entire population (data not shown).
Report of a recent illness was consistently associated with lower total IgA and IgG levels at the cervix for both OC users and non-OC users. Most of the illnesses (68%) reported by the participants were of an acute infectious nature, mainly due to cold. These results were unexpected and suggest the need for additional studies to confirm and better understand these results.
As seen in other smaller studies [18 -21] , current IUD use was associated with higher IgG and IgA levels, although the difference was significant only for IgG. Because IUD use can induce inflammation at the cervix and vagina, it can potentially increase levels of immunoglobulins.
Consistent with previous reports, we observed that the presence of hemoglobin in the cervical specimen was associated with higher IgA and IgG levels [16, 22] . This is expected, given that immunoglobulin levels are higher in serum than in the cervix. We collected cervical secretions before samples were obtained for cytologic analysis, using a gentle sponge to avoid abrading the cervix; hence, blood detected in specimens may reflect a biologically relevant source of immunoglobulin at the cervix rather than a collection-induced artifact. The association of higher immunoglobulin levels with cervical ectopy is also expected, because the glandular endocervical columnar epithelial cells are exposed to the ectocervix during ectopy, making this area more prone to bleeding.
We used specimen weight to approximate collection volume. Although there are limitations to this method for determining volume, it is interesting to note that weight was a strong predictor of immunoglobulin levels at the cervix. For both non-OC users and OC users, IgA and IgG levels were found to decrease with increasing specimen weight. This suggests that the dilution effect of an increased level of cervical mucus during the periovulatory period is an important determinant of immunoglobulin concentrations at the cervix. However, this dilution effect alone is unlikely to fully explain the patterns observed during the cycle, because other covariates were found to be independently associated with IgA and IgG levels in multivariate models that controlled for specimen weight (tables 1 and 2) .
Finally, the degree of change in immunoglobulin levels during the menstrual cycle was not associated with any demographic or lifestyle variables that we evaluated, depending only on the initial immunoglobulin level, the specimen weight, and recent illness.
In summary, we observed a broad range of immunoglobulin levels across women during the menstrual cycle, with the lowest levels observed around the time of ovulation. Although dilution effects resulting from changes in the volume of cervical mucus during the cycle might partially explain the pattern observed, additional factors appear to exert independent effects on immunoglobulin levels at the cervix. OC use and lifetime number of pregnancies were important modifiers of immunoglobulin levels at the cervix, further supporting a role for hormonal factors in defining mucosal immunological responses. Our study did not measure levels of endogenous hormones, precluding a direct evaluation of their effect on cervical levels of immunoglobulins at this time. Implications of our findings include the need for postvaccination surveillance of women who receive the new HPV vaccine, to determine whether and when anti-HPV antibody levels at the cervix decrease below protective levels, as well as the effects of menstrual cycle changes and other factors on the titer of virus-specific antibody and the duration of vaccineinduced protection.
